BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 35117843)

  • 1. PTPRO predicts patient prognosis and correlates with immune infiltrates in human clear cell renal cell carcinoma.
    Gan J; Zhang H
    Transl Cancer Res; 2020 Aug; 9(8):4800-4810. PubMed ID: 35117843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HJURP is a prognostic biomarker for clear cell renal cell carcinoma and is linked to immune infiltration.
    Zhang F; Yuan D; Song J; Chen W; Wang W; Zhu G; Hu B; Chen X; Zhu J
    Int Immunopharmacol; 2021 Oct; 99():107899. PubMed ID: 34217993
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Cheng X; Sun D; Li H; Zhang J; Luo Q; Jin X; Chen Y; Yuan Q; Wang B
    Transl Androl Urol; 2023 Apr; 12(4):642-658. PubMed ID: 37181237
    [TBL] [Abstract][Full Text] [Related]  

  • 4. NUDT1 Could Be a Prognostic Biomarker and Correlated with Immune Infiltration in Clear Cell Renal Cell Carcinoma.
    Lin Y; Zhang F; Jin Y; Zhong Q; Tan W; Liu J; Wu Z
    Appl Bionics Biomech; 2022; 2022():3669296. PubMed ID: 36606241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Upregulated GSDMB in Clear Cell Renal Cell Carcinoma Is Associated with Immune Infiltrates and Poor Prognosis.
    Cui Y; Zhou Z; Chai Y; Zhang Y
    J Immunol Res; 2021; 2021():7753553. PubMed ID: 34957313
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Wang B; Liu B; Luo Q; Sun D; Li H; Zhang J; Jin X; Cheng X; Niu J; Yuan Q; Chen Y
    Transl Cancer Res; 2022 Jul; 11(7):2321-2337. PubMed ID: 35966310
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interleukin 20 receptor subunit beta (IL20RB) predicts poor prognosis and regulates immune cell infiltration in clear cell renal cell carcinoma.
    Zhang H; Liu Y; Wang B; Wang C
    BMC Genom Data; 2022 Jul; 23(1):58. PubMed ID: 35883015
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ALDOB represents a potential prognostic biomarker for patients with clear cell renal cell carcinoma.
    Shao Y; Wu B; Yang Z; Liu Z; Ma Y; Huang H; Liu Y; Wang Z; Hu W; Wang Y; Niu Y
    Transl Androl Urol; 2023 Apr; 12(4):549-571. PubMed ID: 37181232
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PBRM1 mutation and WDR72 expression as potential combinatorial biomarker for predicting the response to Nivolumab in patients with ccRCC: a tumor marker prognostic study.
    Chang Q; Sun J; Zhao S; Li L; Zhang N; Yan L; Fan Y; Liu J
    Aging (Albany NY); 2023 Nov; 15(23):13753-13775. PubMed ID: 38048211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ADAM metallopeptidase domain 12 overexpression correlates with prognosis and immune cell infiltration in clear cell renal cell carcinoma.
    Gao J; Yang D; Xu H; Yang K; Ma J; Xia J; Pan X
    Bioengineered; 2022 Feb; 13(2):2412-2429. PubMed ID: 35094638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comprehensive analysis of the prognostic value and immune infiltration of low expression DBT in clear cell renal cell carcinoma.
    Xie W; Xi P; Liu Y; Zhang Z; Sun T
    Front Pharmacol; 2022; 13():1002588. PubMed ID: 36299888
    [No Abstract]   [Full Text] [Related]  

  • 12. The Downregulation of Prognosis- and Immune Infiltration-Related Gene CYFIP2 Serves as a Novel Target in ccRCC.
    Tong J; Meng X; Lv Q; Yuan H; Li W; Xiao W; Zhang X
    Int J Gen Med; 2021; 14():6587-6599. PubMed ID: 34703279
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Systematic analyses of the role of prognostic and immunological EIF3A, a reader protein, in clear cell renal cell carcinoma.
    Zhang Y; Hua X; Shi H; Zhang L; Xiao H; Liang C
    Cancer Cell Int; 2021 Dec; 21(1):680. PubMed ID: 34923969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance and oncogenic function of NR1H4 in clear cell renal cell carcinoma.
    Huang S; Hou Y; Hu M; Hu J; Liu X
    BMC Cancer; 2022 Sep; 22(1):995. PubMed ID: 36123627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Exploration of the relationships between tumor mutation burden with immune infiltrates in clear cell renal cell carcinoma.
    Zhang C; Li Z; Qi F; Hu X; Luo J
    Ann Transl Med; 2019 Nov; 7(22):648. PubMed ID: 31930049
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Immune-Related Gene HCST as a Novel Biomarker for the Diagnosis and Prognosis of Clear Cell Renal Cell Carcinoma.
    Zhou Y; Wang X; Zhang W; Liu H; Liu D; Chen P; Xu D; Liu J; Li Y; Zeng G; Li M; Wu Z; Zhang Y; Wang X; DiSanto ME; Zhang X
    Front Oncol; 2021; 11():630706. PubMed ID: 33968730
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of MAX dimerization protein 3 (MXD3) predicts poor prognosis in clear cell renal cell carcinoma.
    Zhang F; Liu L; Wu P; Li S; Wei D
    Transl Androl Urol; 2021 Feb; 10(2):785-796. PubMed ID: 33718080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioinformatics screening of prognostic immune-related genes in renal clear cell carcinoma.
    Cui K; Song H; Zhang H; Sun P
    J Appl Genet; 2024 May; ():. PubMed ID: 38780866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comprehensive analysis of MYO6 as a promising biomarker for diagnosis, prognosis, and immunity in clear cell renal cell carcinoma.
    Meng W; Chen B; Jiang Z; Cai B; Ma L; Guan Y
    Transl Cancer Res; 2023 Aug; 12(8):2071-2098. PubMed ID: 37701098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Decreased
    Chen Z; Lv Y; He L; Wu S; Wu Z
    Front Mol Biosci; 2021; 8():657672. PubMed ID: 35096961
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 15.